familial hypercholesterolemia program (SalioGen)

N/A

Report date: 2025/03/18 18:21:47

Base Information

Drug Namefamilial hypercholesterolemia program (SalioGen)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHyperlipoproteinemia Type II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSaliogen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSaliogen Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHyperlipoproteinemia Type II
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A